West Pharmaceutical Services (WST) Total Liabilities (2009 - 2026)

West Pharmaceutical Services (WST) has reported Total Liabilities for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• Quarterly Total Liabilities rose 6.11% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 6.11% YoY) and the FY2025 annual result came in at $1.1 billion, up 13.83% from the prior year.
• Total Liabilities slipped to $1.1 billion in Q2 2026 per WST's latest filing, from $1.1 billion in the prior quarter.
• Over the last five years, Total Liabilities for WST reached as high as $1.1 billion in Q1 2026 and fell as low as $846.0 million in Q3 2022.
• A 5-year average of $967.8 million and a median of $942.4 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities decreased 10.03% — and 2026, when it climbed 19.71%.
• Year by year, Total Liabilities stood at $931.9 million in 2022, then advanced by 1.78% to $948.5 million in 2023, then rose by 1.33% to $961.1 million in 2024, then grew by 13.83% to $1.1 billion in 2025, then slipped by 0.71% to $1.1 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $1.1 billion, $1.1 billion, and $1.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.